$33.77
7.17%
Nasdaq, Wed, Dec 03 2025
ISIN
US87167T2015
Symbol
SNPX

Synaptogenix Inc Stock price

$33.77
+25.84 325.85% 1M
+31.17 1,198.85% 6M
+30.30 873.20% YTD
+30.75 1,018.21% 1Y
-117.23 77.64% 3Y
-52.23 60.73% 5Y
-52.23 60.73% 10Y
-52.23 60.73% 20Y
Nasdaq, Closing price Wed, Dec 03 2025
+2.26 7.17%
ISIN
US87167T2015
Symbol
SNPX

Key metrics

Basic
Market capitalization
-
Enterprise Value
-
Net debt
positive
Cash
$14.8m
Shares outstanding
1.4m
Valuation (TTM | estimate)
P/E
negative | -
P/S
- | -
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
38.2%
Return on Equity
-200.1%
ROCE
-60.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | -
EBITDA
$-9.1m | -
EBIT
$-9.1m | -
Net Income
$-13.0m | -
Free Cash Flow
$-5.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-29.1% | -
EBIT
-29.2% | -
Net Income
-6.1% | -
Free Cash Flow
4.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-9.4
FCF per Share
$-3.6
Short interest
12.4%
Employees
4
Rev per Employee
$0.0
Show more

Is Synaptogenix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,088 stocks worldwide.

Synaptogenix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Synaptogenix Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Synaptogenix Inc forecast:

Buy
86%
Hold
14%

Financial data from Synaptogenix Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.14 5.14
4% 4%
-
- Research and Development Expense 1.05 1.05
39% 39%
-
-9.14 -9.14
29% 29%
-
- Depreciation and Amortization 0.01 0.01
0% 0%
-
EBIT (Operating Income) EBIT -9.15 -9.15
29% 29%
-
Net Profit -13 -13
6% 6%
-

In millions USD.

Don't miss a Thing! We will send you all news about Synaptogenix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Synaptogenix Inc Stock News

Neutral
PRNewsWire
16 days ago
NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today announced that options trading is now available on its four newest leveraged ETFs, which were launched on November 13
Neutral
PRNewsWire
21 days ago
First-to-market funds seek to provide 200% long exposure on exciting growth stories NEW YORK , Nov. 13, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, today launched four new single stock leveraged ETFs. The funds seek to deliver twice (200%) the daily performance of a specific underlying stock.
Neutral
PRNewsWire
23 days ago
Four funds represent first-to-market strategies offering 200% exposure on trending growth stocks NEW YORK , Nov. 11, 2025 /PRNewswire/ -- Tradr ETFs, a provider of ETFs designed for sophisticated investors and professional traders, announced that it expects to launch four new single stock leveraged ETFs on Thursday, November 13. The funds will be listed on Cboe and all four represent first-to-m...
More Synaptogenix Inc News

Company Profile

Synaptogenix, Inc. operates as a biopharmaceutical company. It develops a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease, which is in the clinical testing stage. The firm also evaluates potential therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions. The company was founded on October 31, 2012 and is headquartered in New York, NY.

Head office United States
CEO Alan Tuchman
Employees 4
Founded 2012
Website www.synaptogen.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today